Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

Cited by (1,004)

Items 701–800 of 1,004

1. Spectrum of Endocrine Dysfunction and Association With Disease Severity in Patients With COVID-19: Insights From a Cross-Sectional, Observational Study
   Liza Das, Pinaki R Dutta, Rama Walia, Soham Mukherjee, Vikas Suri, Goverdhan Dutt Puri, Varun Mahajan, Pankaj Malhotra, Shakun Chaudhary, Rahul Gupta et al. · 2021 · Frontiers in Endocrinology
2. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era
   Cori Campbell, Monique Ingrid Andersson, M. Azim Ansari, Olivia Moswela, Siraj Misbah, Paul Klenerman, Philippa Clare Matthews · 2021 · Frontiers in Medicine
3. Lombardy, Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation
   A. Borghesi, S. Golemi, N. Carapella · 2021 · Infectious Diseases
4. Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection
   A. Butt, P. Yan, R. Chotani · 2021 · Liver international (Print)
5. Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients
   Caroline Ruetsch-Chelli, Vesna Brglez, Marion Crémoni, Kévin Zorzi, Céline Fernandez, Sonia Boyer‐Suavet, Sylvia Benzaken, Élisa Demonchy, Karine Risso, Johan Courjon et al. · 2021 · Frontiers in Medicine
6. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
   Wei-Chung Chiou, Meng-Shiuan Hsu, Yun‐Ti Chen · 2021 · Journal of Enzyme Inhibition and Medicinal Chemistry
7. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)
   Cristina Mussini, Marco Falcone, Silvia Nozza, Caterina Sagnelli, Roberto Parrella, Marianna Meschiari, Nicola Petrosillo, Claudio Maria Mastroianni, Antonio Cascio, Chiara Iaria et al. · 2021 · Clinical Microbiology and Infection
8. The PANDEMYC Score. An Easily Applicable and Interpretable Model for Predicting Mortality Associated With COVID-19
   Juan Torres‐Macho, Pablo Ryan, Jorge Alberto Sánchez Valencia, Mario Pérez, Eva Jiménez, Mario Fontán‐Vela, Elsa Izquierdo-García, Inés Fernández Jiménez, Elena Alba Álvaro-Alonso, Andrea Lazaro Cebas et al. · 2020 · Journal of Clinical Medicine
9. Pharmacological treatments of COVID-19
   Adeleh Sahebnasagh, Razieh Avan, Fatemeh Saghafi, Mojataba Mojtahedzadeh, Afsaneh Sadremomtaz, Omid Arasteh, Asal Tanzifi, Fatemeh Faramarzi, Reza Negarandeh, Mohammadreza Safdari et al. · 2020 · Pharmacological Reports
10. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
    Saghir Akhtar, Ibrahim F. Benter, Mohammed Ibn-Mas’ud Danjuma, Suhail A.R. Doi, Syed Shahzad Hasan, Abdella M. Habib · 2020 · Journal of drug targeting
11. SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity
    Wuji Zhang, Brendon Yew Loong Chua, Kevin John Selva, Łukasz Kedzierski, Thomas M. Ashhurst, Ebene R. Haycroft, Suzanne K. Shoffner, Luca Hensen, David F. Boyd, Fiona James et al. · 2022 · Nature Communications
12. Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19
    Tanja Paul, Stephan Ledderose, Harald S. Bartsch, Na Sun, Sarah Hamdy Soliman, Bruno Märkl, Viktoria Ruf, Jochen Wolfgang Herms, Marcel Stern, Oliver Till Keppler et al. · 2022 · Nature Communications
13. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
    Neima Briggs, Michael V. Gormally, Fangyong Li, Sabrina L. Browning, Miriam M. Treggiari, Alyssa R. Morrison, Maudry Laurent-Rolle, Yanhong Deng, Jeanne E. Hendrickson, Christopher A. Tormey et al. · 2021 · PLoS ONE
14. Kidney transplantation and COVID-19 renal and patient prognosis
    Néstor Toapanta, Irina B. Torres, Joana Sellarés, Betty Chamoun, Daniel Serón, Francesc Moreso · 2021 · Clinical Kidney Journal
15. Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients
    Laurence Orchard, Matthew Baldry, Myra Nasim-Mohi, Chantelle Monck, Kordo B. A. Saeed, Michael P. W. Grocott, Ahilanandan Dushianthan · 2021 · Clinical Chemistry and Laboratory Medicine (CCLM)
16. The Role of Glucocorticoids in the Management of COVID-19
    Vasileia Ismini Alexaki, Holger Henneicke · 2020 · Hormone and Metabolic Research
17. COVID-19–Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?
    Federica Francescangeli, Maria Laura De Angelis, Marta Baiocchi, Rachele Rossi, Mauro Biffoni, Ann Zeuner · 2020 · Frontiers in Oncology
18. Commonalities Between COVID-19 and Radiation Injury
    Carmen I. Rios, David R. Cassatt, Brynn A. Hollingsworth, Merriline M. Satyamitra, Yeabsera Tadesse, Lanyn P. Taliaferro, Thomas A. Winters, Andrea L. DiCarlo · 2020 · Radiation Research
19. Thrombosis and COVID-19: The Potential Role of Nutrition
    Αλέξανδρος Τσούπρας, Ronan Lordan, Ioannis Zabetakis · 2020 · Frontiers in Nutrition
20. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report
    Ali Senosi Omrani, Ahmed Zaqout, Anas Baiou et al. · 2020 · Journal of Medical Virology
21. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model
    J. Kreye, S. Reincke, Hans-Christian Kornau et al. · 2020 · bioRxiv
22. Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial
    George Sakoulas, Matthew Geriak, Ravina Kullar, Kristina L. Greenwood, MacKenzie Habib, Anuja Vyas, Mitra Ghafourian, Venkata Naga Kiran Dintyala, Fadi A. Haddad · 2020 · medRxiv
23. COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review
    Peter Brendon Sherren, Marlies Ostermann, Sangita Agarwal, Christopher I. S. Meadows, Nicholas Ioannou, Luigi Camporota · 2020 · British Journal of Anaesthesia
24. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
    Azita H. Talasaz, Hessam Kakavand, Benjamin W. Van Tassell, Maryam Aghakouchakzadeh, Parham Sadeghipour, Steven P. Dunn, Babak Geraiely · 2020 · Cardiovascular Drugs and Therapy
25. Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy
    Denisa Bojková, Rui Costa, Philipp Reus, Marco Bechtel, Mark-Christian Jaboreck, Ruth Olmer, Ulrich Martin, Sandra Ciesek, Martin Michaelis, Jindrich Jr. Cinatl · 2021 · Metabolites
26. Analysis of sex-specific risk factors and clinical outcomes in COVID-19
    Tomi Wei Jun, Sharon Nirenberg, Tziopora Weinberger, Navya Sharma, Elisabet Pujadas, Carlos Cordon‐Cardo, Patricia Kovatch, Kuan‐lin Huang · 2021 · Communications Medicine
27. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis
    Fotios Barkas, Sempastian Filippas-Ntekouan, Maria S. Kosmidou, Evangelos N. Liberopoulos, Angelos Liontos, Haralampos J. Milionis · 2021 · Lara D. Veeken
28. QTc prolongation in COVID ‐19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta‐analysis
    Carlos Diaz‐Arocutipa, Ana Brañez‐Condorena, Adrián Vladimir Hernández · 2021 · Pharmacoepidemiology and Drug Safety
29. Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients
    Varun K. Phadke, Nicholas Scanlon, Stanley C. Jordan, Nadine Rouphael · 2021 · Current Transplantation Reports
30. Coronavirus disease 2019 (COVID-19) and autoimmunity
    Evgeny Lvovich Nasonov · 2021 · Rheumatology Science and Practice
31. Renal Manifestations of Covid-19: Physiology and Pathophysiology
    Zaher Armaly, Safa Kinaneh, Karl L. Skorecki · 2021 · Journal of Clinical Medicine
32. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
    Alejandro Campos-Murguía, Berenice Monserrat Román-Calleja, Israel Vicente Toledo-Coronado, José Alberto González-Regueiro, Alberto Adrián Solís-Ortega, Deyanira Kúsulas-Delint, Mariana Cruz-Contreras, Nabila Cruz-Yedra, Francisco Javier Cubero, Yulia Alexandrowna Nevzorova et al. · 2021 · Digestive and Liver Disease
33. Real‐World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID‐19
    Jessica Myers Franklin, Kueiyu Joshua Lin, Nicolle M. Gatto, Jeremy A. Rassen, Robert J. Glynn, Sebastian Schneeweiß · 2021 · Clinical Pharmacology & Therapeutics
34. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects
    Francesca Polverino, Farrah Kheradmand · 2021 · Frontiers in Medicine
35. The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models
    Scott P Davies, Courtney J. Mycroft‐West, Isabel Pagani, Harriet J. Hill, Yen‐Hsi Chen, Richard Torbjörn Gustav Karlsson, Ieva Bagdonaite, Scott E. Guimond, Zania Stamataki, Marcelo Andrade de Lima et al. · 2021 · Frontiers in Pharmacology
36. The COVID-19 pandemic: a target for surfactant therapy?
    R. Veldhuizen, Y. Zuo, N. Petersen · 2020 · Expert Review of Respiratory Medicine
37. Biocatalytic routes to anti-viral agents and their synthetic intermediates
    Sjoerd Slagman, Wolf‐Dieter Fessner · 2020 · Chemical Society Reviews
38. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease
    S. Hamid, M. Álvares da Silva, K. Burak, Tao Chen, J. Drenth, G. Esmat, R. Gaspar, D. Labrecque, A. Lee, G. Macedo et al. · 2020 · Journal of Clinical Gastroenterology
39. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
    Yaseen M. Arabi, George Panagiotis Chrousos, Gianfranco Umberto Meduri · 2020 · Intensive Care Medicine
40. COVID-19 in the Pediatric Population—Review and Current Evidence
    Shira Rabinowicz, Eyal Leshem, Itai M. Pessach · 2020 · Current Infectious Disease Reports
41. SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus
    Simona Alexandra Iacob, Diana Gabriela Iacob · 2020 · Frontiers in Pharmacology
42. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
    Magdalena Massalska, Włodzimierz Maśliński, Marzena Ciechomska · 2020 · Cells
43. Risk to health from COVID‐19 for anaesthetists and intensivists – a narrative review
    T. M. Cook · 2020 · Anaesthesia
44. Implications of COVID‐19 for an ageing population
    Nicolette R. Holt, Franz–Josef Neumann, John J. McNeil, Allen C Cheng · 2020 · The Medical Journal of Australia
45. An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza
    Edward Burn, Seng-Chan You, Anthony G. Sena et al. · 2020 · medRxiv
46. Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19
    Christian Karagiannidis, Corinna Hentschker, Michael Westhoff, Steffen Weber‐Carstens, Uwe Janssens, Stefan Kluge, Michael A. Pfeifer, Claudia Spies, Tobias Welte, Rolf Rossaint et al. · 2022 · PLoS ONE
47. Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial
    G. Bellingan, F. Jacono, J. Bannard-Smith et al. · 2021 · Intensive Care Medicine
48. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression
    Shuai Yang, Yun Ling, Fang Zhao, Wei Li, Zhigang Song, Lu Wang, Qiuting Li, Mengxing Liu, Ying Tong, Lu Chen et al. · 2022 · Signal Transduction and Targeted Therapy
49. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions
    E. Urano, T. Okamura, Chikako Ono, Shiori Ueno, S. Nagata, H. Kamada, Mahoko Higuchi, Mugi Furukawa, W. Kamitani, Y. Matsuura et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
50. Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection
    Michael J. Christie, Aaron Trent Irving, Samuel C. Forster, Benjamin J. Marsland, Philip M. Hansbro, Paul J. Hertzog, Claudia A. Nold‐Petry, Marcel F. Nold · 2021 · Science Immunology
51. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
    S. Olender, Theresa L. Walunas, E. Martínez et al. · 2021 · Open Forum Infectious Diseases
52. SARS‐CoV‐2 prevalence and maternal‐perinatal outcomes among pregnant women admitted for delivery: Experience from COVID‐19‐dedicated maternity hospital in Jammu, Jammu and Kashmir (India)
    Puneet Gupta, Surender Kumar, Shashi S. Sharma · 2021 · Journal of Medical Virology
53. Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis
    Mallikarjuna Ponnapa Reddy, Ashwin Subramaniam, Afsana Afroz, Baki Billah, Zheng Jie Lim, Alexandr Zubarev, Gabriel Blecher, Ravindranath Tiruvoipati, Kollengode R. Ramanathan, Suei Nee Wong et al. · 2021 · Critical Care Medicine
54. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19
    Gustavo J.S. Pereira, Anderson H.F.F. Leão, Adolfo Garcia Erustes, Ingrid Beatriz de Melo Morais, Talita Aparecida de Moraes Vrechi, Lucas dos Santos Zamarioli, Cássia Arruda Souza Pereira, Laís de Oliveira Marchioro, Letícia Paulino Sperandio, Ísis Valeska Freire Lins et al. · 2021 · International Journal of Molecular Sciences
55. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study
    L. Manenti, U. Maggiore, E. Fiaccadori et al. · 2021 · PLoS ONE
56. COVID-19-associated invasive pulmonary aspergillosis in a tertiary care center in Mexico City
    Mariana Velez-Pintado, Antonio Camiro-Zúñiga, Mercedes Aguilar-Soto, Dalia Cuenca, Moisés Mercado, Brenda Crabtree‐Ramírez, the ARMII study gruop · 2021 · Medical Mycology
57. Availability of Medicines in Community Pharmacy to Manage Patients with COVID-19 in Kenya; Pilot Study and Implications
    Sylvia Adisa Opanga, Nadia Rizvi, Annie Wamaitha, Israel Abebrese Sefah, Brian Godman · 2021 · Scholars Academic Journal of Pharmacy
58. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy
    Nicola Giesen, Rosanne Sprute, Maria Madeleine Rüthrich, Yascha Khodamoradi, Sibylle C. Mellinghoff, Gernot Beutel, Catherina Lueck, Michael Koldehoff, Marcus Hentrich, Michael Sandherr et al. · 2021 · European Journal of Cancer
59. Adjunctive Nutraceutical Therapies for COVID-19
    Lalita Subedi, Stephanie Tchen, Bhakta Prasad Gaire, Bingren R. Hu, Kurt Hu · 2021 · International Journal of Molecular Sciences
60. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
    Juan G. Ripoll, Noud van Helmond, Jonathon W. Senefeld, Chad C. Wiggins, Stephen A. Klassen, Sarah E. Baker, Kathryn F. Larson, Brenna M. Murphy, Kylie J. Andersen, Shane K. Ford et al. · 2021 · Clinical Microbiology Newsletter
61. Functional capacity and rehabilitation strategies in Covid-19 patients: current knowledge and challenges
    Aline Xavier Frota, Marcelo Carvalho Vieira, Carla Cristiane Santos Soares, Paula Simplício da Silva, Gilberto Marcelo Sperandio da Silva, Fernanda de Souza Nogueira Sardinha Mendes, Flavia Mazzoli‐Rocha, Henrique Horta Veloso, Ananda Dutra da Costa, Cristiane da Cruz Lamas et al. · 2021 · Revista da Sociedade Brasileira de Medicina Tropical
62. Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service
    L. Camporota, C. Meadows, S. Ledot · 2021 · The Lancet Respiratory Medicine
63. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients
    Claudia Matteucci, Antonella Minutolo, Emanuela Balestrieri, Vita Petrone, Marialaura Fanelli, Vincenzo Malagnino, Marco Ianetta, Alessandro Giovinazzo, Filippo Barreca, Silvia Di Cesare et al. · 2020 · Open Forum Infectious Diseases
64. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets
    Jimin Xu, Yu Xue, Richard Zhou, Pei‐Yong Shi, Hongmin Li, Jia Zhou · 2020 · Medicinal Research Reviews
65. Covid-19: What now for remdesivir?
    J. Hsu · 2020 · British medical journal
66. A comprehensive review on sarilumab in COVID-19
    Sajad Khiali, Afra Rezagholizadeh, Taher Entezari‐Maleki · 2020 · Expert Opinion on Biological Therapy
67. Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications
    Mainul Haque, Santosh Kumar, Jaykaran Charan, Rohan Bhatt, Salequl Islam, Siddhartha Dutta, Jha Pallavi Abhayanand, Yesh Sharma, Israel Abebrese Sefah, Amanj Baker Kurdi et al. · 2021 · Frontiers in Pharmacology
68. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
    Benjamín Rossi, Lee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, L. Dubret, Louise Baucher, Helene Guillot, Marie‐Anne Bouldouyre, Yves Allenbach, Joe‐Elie Salem et al. · 2020 · Pharmaceuticals
69. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
    Zhibo Liu, Xia Li, Guohui Fan, Fei Zhou, Yeming Wang, Lixue Huang, Jiapei Yu, Luning Yang, Lianhan Shang, Ke Xie et al. · 2020 · Clinical Microbiology and Infection
70. Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report
    Fahad Ali Faqihi, Abdulrahman Mishaal Alharthy, Rayan A. Alshaya, John Papanikolaou, Demetrios James Kutsogiannis, Peter George Brindley, Dimitrios Karakitsos · 2020 · BMC Cardiovascular Disorders
71. SARS‐CoV‐2 vaccination in solid‐organ transplant recipients: What the clinician needs to know
    Maddalena Giannella, Lígia Câmera Pierrotti, Ilkka Helanterä, Oriol Manuel · 2021 · Transplant International
72. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities
    Zena Wehbe, M. Wehbe, R. Iratni · 2021 · Frontiers in Immunology
73. Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe
    Christian Jung, Jesper Fjølner, Raphael Romano Bruno, Bernhard Wernly, Antonio Artigas, Bernardo Bollen Pinto, Joerg C. Schefold, Georg Wolff, Malte Kelm, Michael Beil et al. · 2021 · Critical Care
74. Effect of neuromuscular electrical stimulation on the recovery of people with COVID-19 admitted to the intensive care unit: A narrative review
    Louise C. Burgess, L. Venugopalan, J Badger, Tamsyn Street, Gad Alon, J. C. Jarvis, Thomas William Wainwright, Tamara Everington, Paul N. Taylor, Ian Swain · 2021 · Journal of Rehabilitation Medicine
75. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy
    Cristina Ferreras, Bárbara Pascual-Miguel, Carmen Mestre‐Durán, Alfonso Navarro‐Zapata, Laura Clares Villa, Carla Martín-Cortázar, R. de Paz, A Marcos, JL Vicario, A. Balas et al. · 2021 · Frontiers in Cell and Developmental Biology
76. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
    Mina Thabet Kelleni · 2021 · SN Comprehensive Clinical Medicine
77. Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort study
    A. Xhaard, Constance Xhaard, D et al. · 2021 · British Journal of Haematology
78. Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment
    Bwalya Angel Witika, Pedzisai A. Makoni, Larry L Mweetwa, Pascal Vitalis Ntemi, Mellisa T. R. Chikukwa, Scott Kaba Matafwali, Chiluba Mwila, Steward Mudenda, Jonathan Katandula, Roderick B. Walker · 2020 · Molecules
79. Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019
    Emily Bowman, Cheryl Cameron, Ann Avery, Janelle Gabriel, Aaren Kettelhut, Michelle T. Hecker, Claudia Ute Sontich, Banumathi Tamilselvan, Carmen N. Nichols, Brian Richardson et al. · 2020 · The Journal of Infectious Diseases
80. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies
    Girish Pathangey, Priyal Fadadu, Alexa R. Hospodar, Amr E. Abbas · 2020 · American Journal of Physiology-Lung Cellular and Molecular Physiology
81. Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?
    Roberto Molinaro, Anna Pastò, Francesca Taraballi, Federica Giordano, Jamil A. Azzi, Ennio Tasciotti, Claudia Corbo · 2020 · Nanomaterials
82. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID‐19
    Rongrong Yang, Yong Xiong, Hengning Ke, Tielong Chen, Shicheng Gao · 2020 · European Journal of Clinical Investigation
83. Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology
    A. Bhalla, M. Mukherjee, K. Radford · 2020 · Allergy. European Journal of Allergy and Clinical Immunology
84. COVID-19 Disease
    Christopher P. Conlon, John D. Firth · 2020 · Oxford University Press eBooks
85. Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study
    Vittorio Scaravilli, Amedeo Guzzardella, Fabiana Madotto, Virginia Beltrama, Antonio Muscatello, Giacomo Bellani, Gianpaola Monti, Massimiliano Greco, Antonio Maria Pesenti, Alessandra Bandera et al. · 2022 · Critical Care
86. Public opinion on sharing data from health services for clinical and research purposes without explicit consent: an anonymous online survey in the UK
    Linda A. Jones, Jenny R. Nelder, Joseph M. Fryer, Philip H. Alsop, Michael R. Geary, Mark E. Prince, Rudolf N. Cardinal · 2022 · BMJ Open
87. Cancer and Covid-19: Collectively catastrophic
    Manisha du Plessis, C. Fourie, Johann Riedemann, Willem J.S. de Villiers, Anna‐Mart Engelbrecht · 2021 · Cytokine & Growth Factor Reviews
88. Intubation timing as determinant of outcome in patients with acute respiratory distress syndrome by SARS-CoV-2 infection
    M. Vera, E. Kattan, P. Born et al. · 2021 · Journal of critical care
89. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity
    Lorena Vigón, Daniel Fuertes, Javier García‐Pérez, Montserrat Torres, Sara Rodríguez-Mora, Elena Mateos, Magdalena Corona, Adolfo Sáez, Rosa Malo de Molina, Cristina Navarro et al. · 2021 · Frontiers in Immunology
90. Secondary infections in mechanically ventilated patients with COVID-19: An overlooked matter?
    A. Suárez-de-la-Rica, P. Serrano, Rodrigo de-la-Oliva · 2021 · Revista Espanola de Quimioterapia
91. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity
    Ulfert Rand, Sascha Young Kupke, Hanna Shkarlet, Marc Dominique Hein, Tatjana Hirsch, Pavel Marichal‐Gallardo, Luka Čičin‐Šain, Udo Reichl, Dunja Bruder · 2021 · Cells
92. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
    Alessia Alunno, Aurélie Najm, Pedro Machado, Heidi Bertheussen, Gerd Rüdiger Burmester, Francesco Carubbi, Gabriele De Marco, Roberto Giacomelli, Olivier Hermine, John Dudley Isaacs et al. · 2021 · Annals of the Rheumatic Diseases
93. Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
    O. Badary · 2021 · The Pharmacogenomics Journal
94. The SARS-CoV-2-Inactivating Activity of Hydroxytyrosol-Rich Aqueous Olive Pulp Extract (HIDROX®) and Its Use as a Virucidal Cream for Topical Application
    Yohei Takeda, Dulamjav Jamsransuren, S. Matsuda · 2021 · Viruses
95. Prognostic roles of KL‐6 in disease severity and lung injury in COVID‐19 patients: A longitudinal retrospective analysis
    Kai Deng, Qinghong Fan, Yanhong Yang, Xizi Deng, Ruiying He, Yizhou Tan, Yun Lan, Xilong Deng, Yuejun Pan, Yaping Wang et al. · 2021 · Journal of Medical Virology
96. COVID-19 in ESRD and Acute Kidney Injury
    J. Kooman, F. M. van der Sande · 2020 · Blood Purification
97. Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions
    Eric Allan Meyerowitz, Pritha Sen, Sara R. Schoenfeld, Tomas G. Neilan, Matthew J. Frigault, John H. Stone, Arthur Y. Kim, Michael K. Mansour · 2020 · Clinical Infectious Diseases
98. Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
    S. Larsson, S. Burgess, D. Gill · 2020 · European Respiratory Journal
99. COVID‐19 and education: restructuring after the pandemic
    Maria Irene Bellini, Liset H. M. Pengel, Luciano Potena, Luca Segantini, ESOT COVID‐19 Working Group · 2020 · Transplant International
100. EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic
     T. V. von Oertzen, A. Macerollo, M. Leone et al. · 2020 · European Journal of Neurology